Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

Plain-language summary

This study provides continued (extension) Bosutinib treatment for Chronic Myeloid Leukemia (CML) patients who had previously participated in two specific Bosutinib studies (B1871006 or B1871008). Only patients from those studies were included. It is a non-phase extension study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Pfizer

Intervention

bosutinib

Start date

8/28/2013

Estimated completion

6/5/2020

Countries

United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, Finland, France, Hong Kong, Hungary, India, Italy, Japan, Latvia, Netherlands, Peru, Poland, Russia, Singapore, South Africa, South Korea, Spain, Thailand, Turkey (Türkiye), Ukraine, United Kingdom

Related genes

Locations

• Orlando, United States
• Atlanta, United States
• Atlanta, United States
• Atlanta, United States
• Atlanta, United States
• Atlanta, United States
• Indianapolis, United States
• Sioux City, United States
• Bethesda, United States
• Hawthorne, United States
• Hershey, United States
• Houston, United States
• Houston, United States
• Cd. Autonoma de Buenos Aires, Argentina
• La Plata, Argentina
• Corrientes, Argentina
• Herston, Australia
• Adelaide, Australia
• Charleroi, Belgium
• Campinas, Brazil
• Santo André, Brazil
• Edmonton, Canada
• Vancouver, Canada
• Toronto, Canada
• Montreal, Canada
• Reñaca, Chile
• Reñaca, Chile
• Beijing, China
• Hangzhou, China
• Beijing, China
• Shanghai, China
• Tianjin, China
• Bogota, Colombia
• Helsinki, Finland
• Caen, France
• Nantes, France
• Poitiers, France
• Poitiers, France
• Strasbourg, France
• Chai Wan, Hong Kong

+51

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Only subjects previously participating in two specific studies are eligible to enroll into this study. Enrollment is not open to subjects if not previously enrolled in studies B1871006 or B1871008.

Exclusion Criteria:

* All subjects are excluded unless previously participating in studies B1871006 or B1871008.